American Peptide to expand manufacturing capacity at Vista

Published: 5-May-2010
Manufacturing Ingredients

Move will enable APC to process large-scale peptide production and meet cGMP standards

American Peptide Company (APC), a provider of peptides and peptide-based services to the pharmaceutical and biotech industries, is to ramp up its cGMP (current Good Manufacturing Practice) peptide manufacturing capabilities as well as its service offerings.

The expansion of its facility in Vista, California, US will allow APC to process large-scale peptide production needs while still meeting the high standards of GMP regulations.

The expansion will take place in three main areas of purification, synthesis and lyophilisation.

Four new peptide purification suites will be added for large-scale purification projects. The company also plans to build two new synthesis suites, both for solution phase and solid phase.

For the lyophilisation process, another capacity tray will be added to allow the release of multi-kg single batches of peptide APIs.

‘As the demand for peptide-based therapies increases, we are constantly seeking ways to enhance our operations to meet customer demands for large volumes without compromising our high standards for production,’ said Takahiro Ogata, chief operating officer of APC.

In addition to the expansion of its manufacturing capabilities, APC continues to offer the Total Peptide Management programme as a way of providing customers with increased regulatory support and value-added services. The programme offers a broad portfolio of peptides, and expert consultation to support customers as drug products move from discovery to development and commercialisation.

See more

You may also like

Ingredients

Bachem acquires American Peptide Company

Read more
No financial details have been disclosed

Trending Articles

  1. FDA issues first cGMP warning letter citing AI misuse in pharmaceutical manufacturing A Michigan-based lab has become the subject of the FDA's first dedicated enforcement action on artificial intelligence misuse in drug manufacturing — a landmark event with far-reaching implications for cGMP compliance across the pharmaceutical supply chain
  2. Japanese pharma companies shifting to earlier CDMO outsourcing as peptide complexity increases Neuland Laboratories has reported a notable shift in Japanese pharmaceutical outsourcing patterns during the past 12-24 months, with companies engaging CDMOs earlier in the development cycle
  3. UK REACH reform falls short as industry warns of £500m+ compliance bill The UK chemicals industry has condemned the Government's long-awaited response to the UK REACH Alternative Transitional Registration model consultation, arguing it does little to support growth or innovation
  4. See. Try. Believe. Experience the Lyza 7000 FTIR with a 70-day risk free trial Laboratories can now evaluate the Lyza 7000 FTIR spectrometer in their own environment through a new 70-day, no-cost, no-risk trial program. The initiative allows teams to run real samples, follow existing SOPs, and fully explore the instrument’s capabilities before making a purchase decision
  5. Andelyn Biosciences and ENCell partner to create US-APAC gene therapy manufacturing corridor The company has signed a collaboration agreement with South Korea's ENCell to establish a dual-hemisphere manufacturing platform linking US and Asia-Pacific facilities, enabling in-country production for regional clinical trials

Upcoming event

CHEMUK 2026

20–21 May 2026 | Conference and Exhibition | Birmingham, UK See all

You may also like

Ingredients

Bachem acquires American Peptide Company

No financial details have been disclosed
You need to be a subscriber to read this article.
Click here to find out more.
Ingredients

CPPs: beating drug delivery barriers

Cell-penetrating peptides are a promising tool for cellular import of drug cargos and have been applied in the delivery of a variety of therapeutic molecules. Jyothi Thundimadathil and Archana Gangakhedkar, American Peptide Co, highlight recent application studies
You need to be a subscriber to read this article.
Click here to find out more.
Ingredients

Bicyclic peptides for a new class of targeted drugs

Bicyclic peptides are an emerging class of molecules used to explore new cellular sites not treatable using small molecules or large antibodies. Archana Gangakhedkar, American Peptide Company, reveals some of the properties that offer a new route to targeting diseases
Manufacturing

BD and Suttons Creek collaborate to streamline combination product development for pharma and biotech

The new strategic collaboration will help pharmaceutical and biotech companies reduce development risk and regulatory complexity across drug-device combination products, including biologics and GLP-1 therapies
Manufacturing

Miltenyi Biotec and CHA Biotech collaborate on BaEV lentiviral vector platform

The pair will work to enhance CAR NK cell therapy manufacturing efficiency, combining Miltenyi Bioindustry's baboon envelope lentiviral vector platform with CHA Biotech's NK cell research expertise to improve gene delivery, scalability and cost of goods
Manufacturing

Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services collaborate to support ADC development and manufacturing

Piramal and Ajinomoto Bio-Pharma Services have entered a collaborative arrangement aimed at enhancing their customers’ ADC development and manufacturing programs
Manufacturing

Cipla receives FDA approval for first AB-rated generic of Ventolin HFA in $1.5bn US albuterol market

Indian pharmaceutical company Cipla has secured final FDA approval for its Albuterol Sulfate Inhalation Aerosol, becoming the first AB-rated generic therapeutic equivalent of GlaxoSmithKline's Ventolin HFA
Subscribe now